Tell us about your organization
Tell us about you
Work Email required
Organization required
First Name required
Last Name required
Job Title required
Phone required (###) ###-####, or int ######...
City required
State/Province required
Business Information
Looks like we’re already familiar with you!
Please press next to continue with the survey.
Looks like we’re already familiar with you!
According to your account type you are not eligible to take surveys at this time. If this is a mistake, please contact KLAS.
If you are trying to access KLAS research data and reports, an email has been sent to with a link to login.
If the email doesn't appear in your inbox, ask your IT department to add KLASresearch.com to your company spam filter's "whitelist", and check your email's spam folder.
Membership Commitment
In exchange for giving their feedback, healthcare providers can create an account to get access to industry reports, user commentary, and real-time ratings.
By submitting your account request, you are engaged in patient care as either an employee (or contractor) of your provider organization and that you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically.
To learn more about how we process and protect your personal data, you may view our Privacy policy.
By submitting your account request, you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically. To learn more about how we process and protect your personal data, you may view our Privacy policy.
By submitting your account request, you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically.
To learn more about how we process and protect your personal data, you may view our Privacy policy.
To learn more about how we process and protect your personal data, you may view our Privacy policy.
To learn more about how we process and protect your personal data, you may view our Privacy policy.
Thank You! Your information was submitted successfully!
Next Steps - An email has been sent to . Please follow its instructions to verify your email, and login.
If the email doesn't appear in your inbox, try asking your IT department to add KLASresearch.com to your company spam filter's "whitelist", and checking your email's spam folder.
Thank You! Your information was submitted successfully!
Next Steps - A KLAS representative will contact you to discuss working with KLAS, typically within 24 to 48 hours.
If you have any further questions please contact info@klasresearch.com or 1-800-920-4109.
Surprise! Looks like we already have an account for you.
An email has been sent to blah@blah.com with a link to login.
If the email doesn't appear in your inbox, try asking your IT department to add KLASresearch.com to your company spam filter's "whitelist", and checking your email's spam folder.
Oops! Looks like you don't currently have access.
Your current membership doesn’t include access to this page, but don’t worry we can fix that.
To obtain access to this data,
contact Kathleen Jean
at
KLAS Contact
Who Should Be On Your 340B Speed Dial?
340B HRSA Audit Support
With the potential of being audited by HRSA, providers utilizing the 340B program must take notice of which 340B vendors will help them successfully navigate the audit process. KLAS interviewed providers that have undergone an audit to learn which 340B management system vendors best support providers through an audit, which vendors providers can rely on for future 340B needs, and which vendors decrease WAC spending.
1. SENTRY AND TALYST OFFER BEST PROACTIVE AUDIT SUPPORT
Over 85% of Sentry respondents received on-site help during their HRSA audit. Due to proactive, on-site supportand an in-depth audit training process, Sentry users report the best overall audit support. Talyst provides strong audit preparation and offers proactive phone and on-site support during audits, with over 70% of respondents receiving some form of help. Macro Helix is available by phone and is responsive to questions throughout an audit, taking a more reactive approach. ARxIUM (ABTG) and eAudit Solutions offer almost no assistance throughout the audit process.
2. MACRO HELIX & SENTRY MAINTAIN STAYING POWER IN MARKET
93% of Macro Helix’s providers and 95% of Sentry’s note that their vendor is part of their long-term plans. Users report that both vendors have proactive customer service and strong, easy-to-use tools for 340B management—benefits that prompt them to stay. Talyst customers utilizing the Fully Managed option are slightly happier than those using the software alone; however, the largest pain points for Talyst continue to be product difficulties and slow fixes to problems. ARxIUM (ABTG) and eAudit Solutions are losing customers as they fall behind with new legislative requirements, and both vendors’ satisfaction scores have dropped significantly in the past year, with respondents noting a lack of support.
3. MACRO HELIX RESPONDENTS HAVE GREATEST PERCEIVED DECREASE IN WAC SPENDING
Almost 50% of Macro Helix respondents feel that their 340B system decreases their wholesale acquisition cost (WAC) spending. Macro Helix easily filters out products that do not meet the 340B requirements and adds those that do. Sentry can also effectively filterout WAC products, though users have not seen it help decrease WAC spending as dramatically as Macro Helix respondents. Over 80% of Talyst, ARxIUM (ABTG), and eAudit Solutions respondents feel that their 340B system is increasing their WAC spending. Respondents note difficulties with the products distinguishing which drugs should be 340B and with keeping up to date with changing regulations.
Want to see full details?
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2019 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.